Journal Watch · Circulation · 2026

Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial.

Transthoracic echocardiography revealed that the hyperechoic area corresponding to the biodegradable device began decreasing within the first year after implantation and disappeared on echocardiography by 24 months after implantation.<h4>Conclusions</h4>The novel biodegradable PFO closure device, which disappears on echocardiography within 24 months after implantation, demonstrates noninferiority to the traditional nitinol device in both efficacy and safety.

Zhang F, Dong J, Wei P et al.Circulation3 min readPharma relevance 75/100

DOI: 10.1161/circulationaha.125.074609PMID: 41078120Study type: randomised / controlled clinical trial

TL;DR

Transthoracic echocardiography revealed that the hyperechoic area corresponding to the biodegradable device began decreasing within the first year after implantation and disappeared on echocardiography by 24 months after implantation.<h4>Conclusions</h4>The novel biodegradable PFO closure device, which disappears on echocardiography within 24 months after implantation, demonstrates noninferiority to the traditional nitinol device in both efficacy and safety.

Key findings

  • One patient in the trial group required surgical device removal because of intraprocedural deformation.
  • No deaths, embolism, thrombus on the device, or erosion were observed in either group throughout the entire study period.
  • Transthoracic echocardiography revealed that the hyperechoic area corresponding to the biodegradable device began decreasing within the first year after implantation and disappeared on echocardiography by 24 months after implantation.<h4>Conclusions</h4>The novel biodegradable PFO closure device, which disappears on echocardiography within 24 months after implantation, demonstrates noninferiority to the traditional nitinol device in both efficacy and safety.

Numbers at a glance (from the abstract)

n=96n=9490.63%91.49%95%8.98%10%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

The primary efficacy end point was PFO closure success rate at 6 months postprocedure as demonstrated by contrast echocardiography. We continued to evaluate device-related complications, device disappearance on echocardiography, and closure success rates over a 24-month follow-up period.<h4>Results</h4>Successful PFO closure was achieved in 87 patients (90.63%) in the biodegradable device group and 86 patients (91.49%) in the nitinol device control group. The lower limit of the 95% CI of absolute difference was -8.98%, greater than the predefined noninferiority margin of -10%, confirming that the biodegradable device was not inferior to the nitinol device in terms of closure success.

Full abstract (original)

Background: <h4>Background</h4>Novel biodegradable patent foramen ovale (PFO) closure devices offer a promising therapeutic option. The efficacy and safety of the novel biodegradable devices compared with nitinol devices have not yet been investigated in a randomized clinical trial.<h4>Methods</h4>This multicenter, randomized, noninferiority trial examined whether the novel biodegradable PFO closure device achieves comparable closure success rates as traditional nitinol devices while demonstrating disappearance of the protruding parts of the device on echocardiography. A total of 190 patients with PFO were enrolled and randomly assigned to receive either the biodegradable device (n=96) or the nitinol device (n=94).

What they did: The primary efficacy end point was PFO closure success rate at 6 months postprocedure as demonstrated by contrast echocardiography. We continued to evaluate device-related complications, device disappearance on echocardiography, and closure success rates over a 24-month follow-up period.<h4>Results</h4>Successful PFO closure was achieved in 87 patients (90.63%) in the biodegradable device group and 86 patients (91.49%) in the nitinol device control group. The lower limit of the 95% CI of absolute difference was -8.98%, greater than the predefined noninferiority margin of -10%, confirming that the biodegradable device was not inferior to the nitinol device in terms of closure success.

Results & conclusions: One patient in the trial group required surgical device removal because of intraprocedural deformation. No deaths, embolism, thrombus on the device, or erosion were observed in either group throughout the entire study period. Transthoracic echocardiography revealed that the hyperechoic area corresponding to the biodegradable device began decreasing within the first year after implantation and disappeared on echocardiography by 24 months after implantation.<h4>Conclusions</h4>The novel biodegradable PFO closure device, which disappears on echocardiography within 24 months after implantation, demonstrates noninferiority to the traditional nitinol device in both efficacy and safety.

Abstract © the authors / Circulation (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1161/circulationaha.125.074609 · PubMed 41078120.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking Circulation for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Circulation study find?

Transthoracic echocardiography revealed that the hyperechoic area corresponding to the biodegradable device began decreasing within the first year after implantation and disappeared on echocardiography by 24 months after implantation.<h4>Conclusions</h4>The novel biodegradable PFO closure device, which disappears on echocardiography within 24 months after implantation, demonstrates noninferiority to the traditional nitinol device in both efficacy and safety.

What type of study is this?

It is a randomised / controlled clinical trial, published in Circulation in 2026. The primary efficacy end point was PFO closure success rate at 6 months postprocedure as demonstrated by contrast echocardiography.

Where can I read the original paper?

The original is at the publisher via DOI 10.1161/circulationaha.125.074609. PubMed ID: 41078120. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Zhang F, Dong J, Wei P et al.. Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial.. Circulation (2026). DOI: 10.1161/circulationaha.125.074609.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/transcatheter-closure-of-patent-foramen-ovale-with-a-novel-biodegradable-074609/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides